Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital

Key Points

• Coya Therapeutics received a "Buy" rating from D. Boral Capital, with a price target of $18.00, indicating a potential upside of 162.39% from its current price.
• The company reported a quarterly EPS of ($0.36), missing analysts’ expectations, alongside revenues of $0.16 million, which fell short of the anticipated $0.78 million.
• Institutional ownership of Coya Therapeutics stands at 39.75%, with notable recent investments from firms such as Tower Research Capital and Charles Schwab Investment Management.

D. Boral Capital reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research report sent to investors on Monday,Benzinga reports. They currently have a $18.00 price objective on the stock.

Other analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 13th. Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Lake Street Capital assumed coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They set a "buy" rating and a $16.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $16.50.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock traded up $0.15 during trading on Monday, hitting $6.71. 53,091 shares of the company's stock traded hands, compared to its average volume of 70,154. The firm's fifty day moving average price is $6.10 and its 200 day moving average price is $6.09. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.78 million. As a group, research analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of large investors have recently modified their holdings of COYA. Geode Capital Management LLC lifted its position in shares of Coya Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock worth $863,000 after purchasing an additional 8,267 shares in the last quarter. XTX Topco Ltd acquired a new position in Coya Therapeutics in the fourth quarter valued at approximately $59,000. Tower Research Capital LLC TRC lifted its holdings in Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after buying an additional 4,777 shares during the period. Northern Trust Corp lifted its holdings in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after buying an additional 3,099 shares during the period. Finally, Jane Street Group LLC acquired a new position in Coya Therapeutics in the fourth quarter valued at approximately $74,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.